GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac [Forbes]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Forbes
shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker's vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech. British pharmaceutical company GlaxoSmithKline (GSK) has secured rights to mRNA vaccines it was ... [+] developing with CureVac. GSK said it would pay €400 million ($430 million) upfront to CureVac to take full control of developing and manufacturing mRNA vaccines for COVID-19, seasonal flu and avian influenza (bird flu). The British drugmaker said it would pay an additional €1.05 billion ($1.13 billion) upon reaching various development, regulatory and sales milestones for the shots, as well as royalties from sales. The shots for COVID and flu are in mid stage clinical trials and the deal could see GSK regularly update vaccines to combat seasonal variants and potentially develop , while GSK said the bird flu vaccine is in the earliest stage of clinical trials. Available dat
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNAAccesswire
- Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation 'Wildcard' [Seeking Alpha]Seeking Alpha
- U.S. Government Awards Moderna $176 Million Bird Flu Vaccine Contract [zero hedge]zero hedge
- Does H5N1 avian influenza have pandemic potential? [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 6/28/24 - Form 4
- 6/26/24 - Form 144
- 6/21/24 - Form 4
- MRNA's page on the SEC website